NL9001083A - Beta-cel antigeen. - Google Patents
Beta-cel antigeen. Download PDFInfo
- Publication number
- NL9001083A NL9001083A NL9001083A NL9001083A NL9001083A NL 9001083 A NL9001083 A NL 9001083A NL 9001083 A NL9001083 A NL 9001083A NL 9001083 A NL9001083 A NL 9001083A NL 9001083 A NL9001083 A NL 9001083A
- Authority
- NL
- Netherlands
- Prior art keywords
- cell
- antigen
- beta
- cells
- recognized
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 48
- 102000036639 antigens Human genes 0.000 title claims abstract description 48
- 108091007433 antigens Proteins 0.000 title claims abstract description 48
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title claims abstract description 41
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 56
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 38
- 102000004877 Insulin Human genes 0.000 claims abstract description 19
- 108090001061 Insulin Proteins 0.000 claims abstract description 19
- 229940125396 insulin Drugs 0.000 claims abstract description 19
- 210000004153 islets of langerhan Anatomy 0.000 claims abstract description 7
- 108091005703 transmembrane proteins Proteins 0.000 claims abstract description 3
- 102000035160 transmembrane proteins Human genes 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims description 21
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 20
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 16
- 108091008874 T cell receptors Proteins 0.000 claims description 15
- 230000003248 secreting effect Effects 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 23
- 108090000623 proteins and genes Proteins 0.000 abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 13
- 210000004739 secretory vesicle Anatomy 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000006472 autoimmune response Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 210000000172 cytosol Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010022498 insulinoma Diseases 0.000 description 4
- 208000021255 pancreatic insulinoma Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 230000028023 exocytosis Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100032378 Carboxypeptidase E Human genes 0.000 description 2
- 108010058255 Carboxypeptidase H Proteins 0.000 description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000009171 T-cell vaccination Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 102100023216 40S ribosomal protein S15 Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000009133 Arylsulfatases Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
- 108010064885 HLA-DR3 Antigen Proteins 0.000 description 1
- 101000623543 Homo sapiens 40S ribosomal protein S15 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000009134 Steryl-Sulfatase Human genes 0.000 description 1
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Secondary Cells (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9001083A NL9001083A (nl) | 1990-05-04 | 1990-05-04 | Beta-cel antigeen. |
| AU78632/91A AU652157B2 (en) | 1990-05-04 | 1991-05-06 | Beta cell antigen |
| DE69122864T DE69122864T2 (de) | 1990-05-04 | 1991-05-06 | Beta-zell-antigen |
| JP3508973A JPH05508395A (ja) | 1990-05-04 | 1991-05-06 | ベータ細胞抗原 |
| EP91909160A EP0528886B1 (de) | 1990-05-04 | 1991-05-06 | Beta-zell-antigen |
| CA002082162A CA2082162A1 (en) | 1990-05-04 | 1991-05-06 | Beta cell antigen |
| PCT/NL1991/000077 WO1991017186A1 (en) | 1990-05-04 | 1991-05-06 | Beta cell antigen |
| DK91909160.3T DK0528886T3 (da) | 1990-05-04 | 1991-05-06 | Beta-celleantigen |
| AT91909160T ATE144529T1 (de) | 1990-05-04 | 1991-05-06 | Beta-zell-antigen |
| US12/381,585 US20090226930A1 (en) | 1990-05-04 | 2009-03-13 | Beta cell antigen |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9001083 | 1990-05-04 | ||
| NL9001083A NL9001083A (nl) | 1990-05-04 | 1990-05-04 | Beta-cel antigeen. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL9001083A true NL9001083A (nl) | 1991-12-02 |
Family
ID=19857067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL9001083A NL9001083A (nl) | 1990-05-04 | 1990-05-04 | Beta-cel antigeen. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090226930A1 (de) |
| EP (1) | EP0528886B1 (de) |
| JP (1) | JPH05508395A (de) |
| AT (1) | ATE144529T1 (de) |
| AU (1) | AU652157B2 (de) |
| CA (1) | CA2082162A1 (de) |
| DE (1) | DE69122864T2 (de) |
| DK (1) | DK0528886T3 (de) |
| NL (1) | NL9001083A (de) |
| WO (1) | WO1991017186A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674692A (en) * | 1991-09-06 | 1997-10-07 | Baekkeskov; Steinunn | Methods for diabetes susceptibility assessment in asymptomatic patients |
| WO1994024564A1 (en) | 1993-04-16 | 1994-10-27 | The Regents Of The University Of California | Methods for diabetes susceptibility assessment in asymptomatic patients |
| DE4337396A1 (de) * | 1993-10-26 | 1995-04-27 | Beiersdorf Ag | Humane Zellinien mit Langerhans-Zell-Charakteristik |
| AU3094795A (en) * | 1994-07-08 | 1996-02-09 | Trustees Of Dartmouth College | Proinsulin peptide compounds for detecting and treating type i diabetes |
| US6509165B1 (en) | 1994-07-08 | 2003-01-21 | Trustees Of Dartmouth College | Detection methods for type I diabetes |
| AU4482896A (en) * | 1995-01-31 | 1996-08-21 | Novo Nordisk A/S | A method of diagnosing preclinical diabetes |
| EP0874901A2 (de) * | 1995-12-20 | 1998-11-04 | Institute of Molecular and Cell Biology | Reagens zur diagnostik von diabetes |
| WO1997032984A1 (en) * | 1996-03-06 | 1997-09-12 | Zymogenetics, Inc. | DIABETES MELLITUS 37 kD AUTOANTIGEN PROTEIN-TYROSINE PHOSPHATASE |
| FR2847263B1 (fr) | 2002-11-18 | 2006-01-13 | Commissariat Energie Atomique | Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans |
| US10372746B2 (en) | 2005-10-26 | 2019-08-06 | Cortica, Ltd. | System and method for searching applications using multimedia content elements |
| US10380267B2 (en) | 2005-10-26 | 2019-08-13 | Cortica, Ltd. | System and method for tagging multimedia content elements |
| US10380623B2 (en) | 2005-10-26 | 2019-08-13 | Cortica, Ltd. | System and method for generating an advertisement effectiveness performance score |
| US10180942B2 (en) | 2005-10-26 | 2019-01-15 | Cortica Ltd. | System and method for generation of concept structures based on sub-concepts |
| US9372940B2 (en) | 2005-10-26 | 2016-06-21 | Cortica, Ltd. | Apparatus and method for determining user attention using a deep-content-classification (DCC) system |
| US10733326B2 (en) | 2006-10-26 | 2020-08-04 | Cortica Ltd. | System and method for identification of inappropriate multimedia content |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020083451A1 (en) * | 2000-12-21 | 2002-06-27 | Gill Komlika K. | User-friendly electronic program guide based on subscriber characterizations |
| US20030145326A1 (en) * | 2002-01-31 | 2003-07-31 | Koninklijke Philips Electronics N.V. | Subscription to TV channels/shows based on recommendation generated by a TV recommender |
| JP4193629B2 (ja) * | 2003-07-25 | 2008-12-10 | ソニー株式会社 | 画面表示装置，プログラム，および画面表示方法 |
| US20050160458A1 (en) * | 2004-01-21 | 2005-07-21 | United Video Properties, Inc. | Interactive television system with custom video-on-demand menus based on personal profiles |
-
1990
- 1990-05-04 NL NL9001083A patent/NL9001083A/nl not_active Application Discontinuation
-
1991
- 1991-05-06 JP JP3508973A patent/JPH05508395A/ja active Pending
- 1991-05-06 CA CA002082162A patent/CA2082162A1/en not_active Abandoned
- 1991-05-06 DE DE69122864T patent/DE69122864T2/de not_active Expired - Fee Related
- 1991-05-06 DK DK91909160.3T patent/DK0528886T3/da active
- 1991-05-06 WO PCT/NL1991/000077 patent/WO1991017186A1/en active IP Right Grant
- 1991-05-06 EP EP91909160A patent/EP0528886B1/de not_active Expired - Lifetime
- 1991-05-06 AU AU78632/91A patent/AU652157B2/en not_active Ceased
- 1991-05-06 AT AT91909160T patent/ATE144529T1/de not_active IP Right Cessation
-
2009
- 2009-03-13 US US12/381,585 patent/US20090226930A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2082162A1 (en) | 1991-11-05 |
| JPH05508395A (ja) | 1993-11-25 |
| US20090226930A1 (en) | 2009-09-10 |
| WO1991017186A1 (en) | 1991-11-14 |
| ATE144529T1 (de) | 1996-11-15 |
| AU652157B2 (en) | 1994-08-18 |
| DE69122864T2 (de) | 1997-06-05 |
| AU7863291A (en) | 1991-11-27 |
| EP0528886B1 (de) | 1996-10-23 |
| DE69122864D1 (en) | 1996-11-28 |
| DK0528886T3 (da) | 1997-04-21 |
| EP0528886A1 (de) | 1993-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090226930A1 (en) | Beta cell antigen | |
| Bonomo et al. | Thymus epithelium induces tissue-specific tolerance. | |
| Somoza et al. | Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. | |
| Wegmann et al. | Insulin‐specific T cells are a predominant component of islet infiltrates in pre‐diabetic NOD mice | |
| Roep et al. | T-cell reactivity to β-cell membrane antigens associated with β-cell destruction in IDDM | |
| Bergman et al. | Islet-specific T-cell clones from the NOD mouse respond to β-granule antigen | |
| Casares et al. | Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide–MHC class II chimera | |
| Chiodini et al. | The cellular immunology of bovine paratuberculosis: the predominant response is mediated by cytotoxic gamma/delta T lymphocytes which prevent CD4+ activity | |
| US8906383B2 (en) | T cell receptor having binding affinity for a peptide-MHC complex and uses thereof | |
| AU772451B2 (en) | Modified exosomes and uses | |
| Herberman et al. | The expression of histocompatibility antigens on cellular and subcellular membranes | |
| Brooks-Worrell et al. | Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. | |
| Xu et al. | Human CD4+ CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance | |
| Varela-Calvino et al. | Apportioning blame: autoreactive CD4+ and CD8+ T cells in type 1 diabetes | |
| Schuurman et al. | The thymus in “bare lymphocyte” syndrome: significance of expression of major histocompatibility complex antigens on thymic epithelial cells in intrathymic T-cell maturation | |
| Huang et al. | Antigen-specific regulation of IgE antibodies by non-antigen–specific γδ T cells | |
| Burns et al. | A human leukaemic cell expressing hybrid membrane phenotypes | |
| Hagopian et al. | Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina | |
| Klareskog et al. | Binding of HLA antigen-containing liposomes to bacteria | |
| Parr | The absence of H-2 antigens from mouse pancreatic beta-cells demonstrated by immunoferritin labeling. | |
| Taguchi et al. | Analysis of PI (phosphatidylinositol)-anchoring antigens in a patient of paroxysmal nocturnal hemoglobinuria (PNH) reveals deficiency of 1F5 antigen (CD59), a new complement-regulatory factor | |
| Bleesing et al. | Human T cell activation induces the expression of a novel CD45 isoform that is analogous to murine B220 and is associated with altered O-glycan synthesis and onset of apoptosis | |
| Korbutt et al. | Natural human antibody‐mediated destruction of porcine neonatal islet cell grafts | |
| Chen et al. | The development and application of HLA tetramers in the detection, characterization and therapy of type 1 diabetes mellitus | |
| Feili-Hariri et al. | Functional consequences of the binding of MHC class ll-derived peptides to MHC class II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| BV | The patent application has lapsed |